Format

Send to

Choose Destination
Transl Psychiatry. 2019 Oct 4;9(1):247. doi: 10.1038/s41398-019-0573-8.

Identification of HIVEP2 as a dopaminergic transcription factor related to substance use disorders in rats and humans.

Author information

1
School of Life Science, Beijing Institute of Technology, 100081, Beijing, China.
2
Laboratory of Psychiatric Genomics, McLean Hospital, Belmont, MA, 02478, USA.
3
Department of Neurology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, P. R. China.
4
Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana, 46202, USA.
5
Laboratory of Psychiatric Genomics, McLean Hospital, Belmont, MA, 02478, USA. zlin@mclean.harvard.edu.

Abstract

Playing an important role in the etiology of substance use disorder (SUD), dopamine (DA) neurons are subject to various regulations but transcriptional regulations are largely understudied. For the first time, we report here that the Human Immunodeficiency Virus Type I Enhancer Binding Protein 2 (HIVEP2) is a dopaminergic transcriptional regulator. HIVEP2 is expressed in both the cytoplasm and nuclei of DA neurons. Therein, HIVEP2 can target the intronic sequence GTGGCTTTCT of SLC6A3 and thereby activate the gene. In naive rats from the bi-directional selectively bred substance-preferring P vs -nonpreferring NP rat model of substance abuse vulnerability, increased gene activity in males was associated with the vulnerability, whereas decreased gene activity in the females was associated with the same vulnerability. In clinical subjects, extensive and significant HIVEP2-SLC6A3 interactions were observed for SUD. Collectively, HIVEP2-mediated transcriptional mechanisms are implicated in dopaminergic pathophysiology of SUD.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center